Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Cost-effectiveness of posterior lumbar interbody fusion and/or transforaminal lumbar interbody fusion for grade 1 lumbar spondylolisthesis: a 5-year Quality Outcomes Database study
Yee, Timothy J., Liles, Campbell, Johnson, Sarah E. , DiGiorgio, Anthony M. , Alan, Nima , Coric, Domagoj , Potts, Eric A. , Bisson, Erica F. , Knightly, John J. , Fu, Kai-Ming, Foley, Kevin T. , Shaffrey, Mark E., Bydon, Mohamad , Chou, Dean , Chan, Andrew K. , Meyer, Scott A., Shaffrey, Christopher I. , Slotkin, Jonathan R., Wang, Michael Y. , Haid, Regis W., Glassman, Steven D. , Virk, Michael S., Mummaneni, Praveen V., Ambati, Vardhaan , Asher, Anthony L., Virk, Michael S., Mummaneni, Praveen V. , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | August 17, 2024 | Volume: 41 | Issue: 5 | Pages: 596-603

10.3171/2024.5.spine24112 | PMID 39151203 Get It

OBJECTIVE Posterior lumbar interbody fusion (PLIF) and/or transforaminal lumbar interbody fusion (TLIF), referred to as "PLIF/TLIF," is a commonly performed operation for lumbar spondylolisthesis. Its long-term cost-effectiveness has not been well described. The aim of this study was to determine the 5-year cost-effectiveness of PLIF/TLIF for grade 1 degenerative lumbar spondylolisthesis using prospective data collected from the multicenter Quality Outcomes Database (QOD). METHODS Patients enrolled in the prospective, multicenter QOD grade 1 lumbar spondylolisthesis module were included if they underwent single-stage PLIF/TLIF. EQ-5D scores at baseline, 3 months, 12 months, 24 months, 36 months, and 60 months were used to calculate gains in quality-adjusted life years (QALYs) associated with surgery relative to preoperative baseline. Healthcare-related costs associated with the index surgery and related reoperations were calculated using Medicare reimbursement–based cost estimates and validated using price transparency diagnosis-related group (DRG) charges and Medicare charge-to-cost ratios (CCRs). Cost per QALY gained over 60 months postoperatively was assessed. RESULTS Across 12 surgical centers, 385 patients were identified. The mean patient age was 60.2 (95% CI 59.1–61.3) years, and 38% of patients were male. The reoperation rate was 5.7%. DRG 460 cost estimates were stable between our Medicare reimbursement–based models and the CCR-based model, validating the focus on Medicare reimbursement. Across the entire cohort, the mean QALY gain at 60 months postoperatively was 1.07 (95% CI 0.97–1.18), and the mean cost of PLIF/TLIF was $31,634. PLIF/TLIF was associated with a mean 60-month cost per QALY gained of $29,511. Among patients who did not undergo reoperation (n = 363), the mean 60-month QALY gain was 1.10 (95% CI 0.99–1.20), and cost per QALY gained was $27,591. Among those who underwent reoperation (n = 22), the mean 60-month QALY gain was 0.68 (95% CI 0.21–1.15), and the cost per QALY gained was $80,580. CONCLUSIONS PLIF/TLIF for degenerative grade 1 lumbar spondylolisthesis was associated with a mean 60-month cost per QALY gained of $29,511 with Medicare fees. This is far below the well-established societal willingness-to-pay threshold of $100,000, suggesting long-term cost-effectiveness. PLIF/TLIF remains cost-effective for patients who undergo reoperation.
Predictors of patient satisfaction in the surgical treatment of cervical spondylotic myelopathy
Schüpper, Alexander J. , DiDomenico, Joseph D., Johnson, Sarah E. , Bisson, Erica F. , Bydon, Mohamad , Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Shaffrey, Christopher I., Gottfried, Oren N., Park, Christine , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Chan, Andrew K. , Tumialán, Luis M. , Chou, Dean , Haid, Regis W., Mummaneni, Praveen V., Uribe, Juan S. , Turner, Jay D. , Farber, Samuel Harrison , Fu, Kai-Ming, Shaffrey, Christopher I. , Park, Paul , Mummaneni, Praveen V. , Uribe, Juan S.

Mayo Clinic

Journal of Neurosurgery: Spine | August 17, 2024 | Volume: 41 | Issue: 5 | Pages: 611-618

10.3171/2024.5.spine24326 | PMID 39151188 Get It

OBJECTIVE Patients with cervical spondylotic myelopathy (CSM) experience progressive neurological impairment. Surgical intervention is often pursued to halt neurological symptom progression and allow for recovery of function. In this paper, the authors explore predictors of patient satisfaction following surgical intervention for CSM. METHODS This is a retrospective review of prospectively collected data from the multicenter Quality Outcomes Database. Patients who underwent surgical intervention for CSM with a minimum follow-up of 2 years were included. Patient-reported satisfaction was defined as a North American Spine Society (NASS) satisfaction score of 1 or 2. Patient demographics, surgical parameters, and outcomes were assessed as related to patient satisfaction. Patient quality of life scores were measured at baseline and 24-month time points. Univariate regression analyses were performed using the chi-square test or Student t-test to assess patient satisfaction measures. Multivariate logistic regression analysis was conducted to assess for factors predictive of postoperative satisfaction at 24 months. RESULTS A total of 1140 patients at 14 institutions with CSM who underwent surgical intervention were included, and 944 completed a patient satisfaction survey at 24 months postoperatively. The baseline modified Japanese Orthopaedic Association (mJOA) score was 12.0 ± 2.8. A total of 793 (84.0%) patients reported satisfaction (NASS score 1 or 2) after 2 years. Male and female patients reported similar satisfaction rates (female sex: 47.0% not satisfied vs 48.5% satisfied, p = 0.73). Black race was associated with less satisfaction (26.5% not satisfied vs 13.2% satisfied, p < 0.01). Baseline psychiatric comorbidities, obesity, and length of stay did not correlate with 24-month satisfaction. Crossing the cervicothoracic junction did not affect satisfactory scores (p = 0.19), and minimally invasive approaches were not associated with increased patient satisfaction (p = 0.14). Lower baseline numeric rating scale neck pain scores (5.03 vs 5.61, p = 0.04) and higher baseline mJOA scores (12.28 vs 11.66, p = 0.01) were associated with higher satisfaction rates. CONCLUSIONS Surgical treatment of CSM results in a high rate of patient satisfaction (84.0%) at the 2-year follow-up. Patients with milder myelopathy report higher satisfaction rates, suggesting that intervention earlier in the disease process may result in greater long-term satisfaction.
NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024
Benson, Al B. , Adam, Mohamed A. , Chang, George J. , Chen, Yi-Jen, Cooper, Harry S. , Deming, Dustin A. , Garrido‐Laguna, Ignacio , Grem, Jean L. , Haste, Paul, Hecht, J. Randolph, Hoffe, Sarah E. , Hunt, Steven R., Johung, Kimberly L. , Joseph, Nora, Kirilcuk, Natalie, Krishnamurthi, Smitha , Malla, Midhun , Maratt, Jennifer K. , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Mulcahy, Mary F. , Nurkin, Steven, Parikh, Aparna, Patel, Hitendra , Shibata, David , Shogan, Benjamin D. , Skibber, John M., Sofocleous, Constantinos T. , Tavakkoli, Anna , Willett, Christopher G. , Wu, Christina, Jones, Frankie, Gurski, Lisa A., Meyerhardt, Jeffrey A , Venook, Alan P. , Chen, Yi‐Jen , Ciombor, Kristen K. , Cohen, Stacey A. , Hussan, Hisham , Miller, Eric D. , Patel, Hitendra, Pedersen, Katrina S. , Saltz, Leonard B. , Schneider, Charles John

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 16, 2024 | Volume: 22 | Issue: 6 | Pages: 366-375

10.6004/jnccn.2024.0041 | PMID 39151454 Get It

The determination of an optimal treatment plan for an individual patient with rectal cancer is a complex process. In addition to decisions relating to the intent of rectal cancer surgery (ie, curative or palliative), consideration must also be given to the likely functional results of treatment, including the probability of maintaining or restoring normal bowel function/anal continence and preserving genitourinary functions. Particularly for patients with distal rectal cancer, finding a balance between curative-intent therapy while having minimal impact on quality of life can be challenging. Furthermore, the risk of pelvic recurrence is higher in patients with rectal cancer compared with those with colon cancer, and locally recurrent rectal cancer is associated with a poor prognosis. Careful patient selection and the use of sequenced multimodality therapy following a multidisciplinary approach is recommended. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Rectal Cancer, including the addition of endoscopic submucosal dissection as an option for early-stage rectal cancer, updates to the total neoadjuvant therapy approach based on the results of recent clinical trials, and the addition of a “watch-and-wait” nonoperative management approach for clinical complete responders to neoadjuvant therapy.
Interaction of simultaneous hypoxia and baroreflex loading on control of sympathetic action potential subpopulations
Boyes, Natasha G. , Baker, Sarah E. , Nicholson, Wayne T. , Joyner, Michael J. , Shoemaker, J. Kevin , Limberg, Jacqueline K. , Klassen, Stephen A , Baker, Sarah E , Joyner, Michael J , Shoemaker, J Kevin , Limberg, Jacqueline K , Klassen, Stephen A.

Mayo Clinic

Journal of Neurophysiology | August 14, 2024 | Volume: 132 | Issue: 3 | Pages: 1087-1097

10.1152/jn.00277.2024 | PMID 39140588 Get It

This study provides a novel understanding on baroreflex control of efferent sympathetic nervous system activity during competing stressors: baroreflex loading and peripheral chemoreflex activation. We show chemoreflex activation buffers baroreflex-mediated reductions in sympathetic nervous system activity. More importantly, baroreflex loading reduced baroreflex threshold gain of sympathetic action potential clusters and this reduction withstood chemoreflex activation. These data suggest the arterial baroreflex holds a primary regulatory role over medium-sized sympathetic neurons despite competing chemoreflex signals.
Validation of an Epigenetic Prognostic Assay to Accurately Risk-Stratify Patients With Barrett Esophagus
Laun, Sarah , Kann, Lisa , Braun, Jerome J., Gilbert, Stacey, Lunz, Daniel, Pierre, Francia , Kalra, Andrew , Tsai, Hua‐Ling , Wang, Hao , Cheng, Yulan , Ahmed, Yousra , Wang, Kenneth K, Leggett, Cadman L. , Cellini, Ashley, Ioffe, Olga B. , Omstead, Ashten N., Jobe, Blair A. , Korman, Louis Y. , Cornish, Drew, Zellenrath, Pauline A. , Perpetua, Lorrie A., Greenwald, Bruce D. , Maddala, Tara, Meltzer, Stephen J. , Tsai, Hua-Ling , Wang, Hao , Ahmed, Yousra , Leggett, Cadman L , Ioffe, Olga B , Zaidi, Ali Hussainy , Cornish, Drew , Zellenrath, Pauline , Spaander, Manon , Kuipers, Ernst , Greenwald, Bruce D , Meltzer, Stephen J , Braun, Jerome, Ma, Ke , Jit, Simran, Kuipers, Ernst J.

Mayo Clinic

American Journal of Gastroenterology | August 14, 2024 | Volume: 120 | Issue: 6 | Pages: 1296-1306

10.14309/ajg.0000000000003030 | PMID 39140473 Get It

INTRODUCTION: Esophageal adenocarcinoma (EAC) is the second-most lethal cancer in the United States, with Barrett esophagus (BE) being the strongest risk factor. Assessing the future risk of neoplastic progression in patients with BE is difficult; however, high-grade dysplasia (HGD) and early EAC are treatable by endoscopic eradication therapy (EET), with survival rates of 90%. Thus, it would be beneficial to develop a molecular assay to identify high-risk patients, who merit more frequent endoscopic surveillance or EET, as well as low-risk patients, who can avoid EET and undergo less frequent surveillance. METHODS: Deidentified endoscopic biopsies were acquired from 240 patients with BE at 6 centers and confirmed as future progressors or nonprogressors. Tissues were analyzed by a set of methylation-specific biomarker assays. Test performance was assessed in an independent validation set using 4 stratification levels: low risks, low-moderate risks, high-moderate risks, and high risks. RESULTS: Relative to patients in the low-risk group, high-risk patients were 15.2 times more likely to progress within 5 years to HGD or EAC. For patients in the high-risk category, the average risk of progressing to HGD or EAC within 5 years was 21.5%, 4-fold the BE population prevalence within 5 years, whereas low-risk patients had a progression risk of only 1.85%. DISCUSSION: This clinical assay, Esopredict, stratifies future neoplastic progression risk to identify higher-risk patients with BE who can benefit from EET or more frequent surveillance and lower-risk patients who can benefit from reduced surveillance.
Comparison of Outcomes After Cochlear Implantation in a Veteran Versus Nonveteran Population
Tripathi, Siddhant H. , Adams, Sarah M. , Petito, Gabrielle T. , Grisel, Jedidiah J. , Breen, Joseph T. , Patil, Reena Dhanda , Breen, Joseph, Wong, Eric M., Shapiro, Scott

Mayo Clinic

Otology & Neurotology Open | August 12, 2024 | Volume: 4 | Issue: 3 | Pages: e058

10.1097/ono.0000000000000058 | PMID 39328868 Get It

Objective: To evaluate for equivalence in postoperative changes of speech recognition scores in a veteran patient population undergoing cochlear implantation (CI) compared to matched nonveteran patients. Study Design: Retrospective chart review. Setting: Tertiary referral center. Patients: A total of 83 veteran patients who underwent CI at a single Veterans Affairs Medical Center (VA cohort) were matched to 83 nonveteran patients from the Health Insurance Portability and Accountability Act-secure, Encrypted, Research, Management and Evaluation Solution database (HERMES cohort) based on age, sex, and baseline Consonant–Nucleus–Consonant (CNC) scores. Intervention: Patients underwent CI. Main Outcome Measures: Comparison of postoperative CNC and Arizona Biomedical Institute recognition scores. Results: The mean difference and lower confidence interval of CNC scores between matched Veterans Affairs and HERMES cohorts were within a −ΔNI boundary of −15% at the 3-month (mean = 6.15, lower confidence interval = −2.38), 6-month (mean = 7.36, lower confidence interval = −2.21), and 12-month (mean = 4.03, lower confidence interval = −4.88) postoperative time points. The mean difference and lower confidence interval of Arizona Biomedical Institute scores between cohorts were within the −ΔNI boundary of −30% at 3 months (mean = 1, lower confidence interval = −8.71), 6 months (mean = 0.31, lower confidence interval = −12.30), and 12 months (mean = 0.72, lower confidence interval = −10.48). Conclusion: Our veteran population demonstrated improvements in speech recognition scores after CI comparable to a matched nonveteran population. Although veterans face unique factors that affect their hearing, access to medical care, and baseline general health, these findings affirm appropriate veteran candidates should be offered CI.
CYP3A4 Poor and Intermediate Metabolizers Have a Higher Rate of Steroid-Induced Intraocular Pressure Response
Wright, Jessica , Xu, Sarah Chao Ying , Wong, M , Melik, Razan M. El , Hodge, David O. , Sit, Arthur J. , Xu, Sarah C , Wong, Mitchell H , Hodge, David, Wright, Jessica A , El Melik, Razan M , Sit, Arthur J

Mayo Clinic

Journal of Glaucoma | August 12, 2024 | Volume: 34 | Issue: 2 | Pages: e9-e12

10.1097/ijg.0000000000002482 | PMID 39133066 Get It

Purpose: Evaluate the relationship between CYP3A4 phenotype, the gene encoding the enzyme that metabolizes exogenous steroids, and the rate of steroid-induced intraocular pressure (IOP) response. Materials and Methods: Lymphocyte-derived DNA sequencing of CYP3A4 from 10073 patients was completed using the PGRN-Seq assay. Subjects with CYP3A4 intermediate metabolizer or slower phenotypes were identified and compared with controls matched by age, race, and sex. All subjects had at least 3 eye exams with at least an exam while on topical/systemic/local steroid in any body location except the eye. Patients with pre-existing glaucoma or glaucoma suspects were excluded. Results: Of the 10,073 patients, there were 63 patients who had CYP3A4 poor or intermediate metabolizer phenotype. Of the 63 patients, 22 had documented steroid use. Fifty-nine percent (13/22) of patients with CYP3A4 poor/intermediate metabolizer had a steroid-induced IOP response of 3 mm Hg or more, significantly higher compared with 23% (5/22) of matched controls (P=0.031). Although more poor/intermediate metabolizers were steroid responders, the average IOP elevation in steroid responders in both groups was similar (5.0±2.5 mm Hg in CYP3A4 poor/intermediate metabolizers compared with 4.1±2.1 mm Hg in controls, P=0.327). Family history of glaucoma was similar in both groups (7/22 vs. 8/22, P=1.0). Conclusion: Reduced CYP3A4 phenotypes may help identify patients at a higher risk of steroid-induced IOP elevation.
A Vaping Cessation Text Message Program for Adolescent E-Cigarette Users
Cha, Sarah , Funsten, Anna L., Edwards, Giselle , Graham, Amanda L. , Jacobs, Megan A , Amato, Michael S. , Papandonatos, George D.

Mayo Clinic

JAMA | August 7, 2024 | Volume: 332 | Issue: 9 | Pages: 713

10.1001/jama.2024.11057 | PMID 39110436 Get It

ImportanceE-cigarettes are the most commonly used tobacco product among adolescents. Despite known harms of nicotine exposure among teens, there are no empirically tested vaping cessation interventions.ObjectiveTo compare the effectiveness of a text message program for nicotine vaping cessation among adolescents with assessment-only control.Design, Setting, and ParticipantsA parallel, 2-group, double-blind, individually randomized clinical trial with follow-ups at 1 and 7 months after randomization was conducted from October 1, 2021, to October 18, 2023. Participants were recruited via social media ads; the intervention was delivered via text message; and assessments were completed online or by telephone. Eligible individuals were US residents aged 13 to 17 years who reported past 30-day e-cigarette use, were interested in quitting within 30 days, and owned a mobile phone with an active text message plan. To optimize study retention, all participants received monthly assessments via text message about e-cigarette use.InterventionsAssessment-only controls (n = 744) received only study retention text messages. Intervention participants (n = 759) also received an automated, interactive text message program for vaping cessation that delivers cognitive and behavioral coping skills training and social support.Main Outcomes and MeasuresThe primary outcome was self-reported 30-day point-prevalence abstinence from vaping at 7 months analyzed as intention-to-treat, with missingness coded as vaping.ResultsAmong n = 1503 adolescents randomized, average age was 16.4 (SD, 0.8) years. The sample was 50.6% female, 42.1% male, and 7.4% nonbinary/other; 10.2% Black/African American, 62.6% White, 18.5% multiracial, and 8.7% another race; 16.2% Hispanic; 42.5% sexual minority; and 76.2% vaped within 30 minutes of waking. The 7-month follow-up rate was 70.8%. Point-prevalence abstinence rates were 37.8% (95% CI, 34.4%-41.3%) among intervention participants and 28.0% (95% CI, 24.9%-31.3%) among control participants (relative risk, 1.35 [95% CI, 1.17-1.57]; P &amp;lt; .001). No baseline variables moderated the treatment-outcome relationship. There was no evidence that adolescents who quit vaping transitioned to combustible tobacco products.Conclusions and RelevanceA tailored, interactive text message intervention increased self-reported vaping cessation rates among adolescents recruited via social media channels.Trial RegistrationClinicalTrials.gov Identifier: NCT04919590
Advancing Care Team Adoption of Electronic Health Record Systems for Cancer Symptom Management: Findings From a Hybrid Type II, Cluster-Randomized, Stepped-Wedge Trial
Austin, Jessica D. , Fischer, Kristin , Ridgeway, Jennifer L. , Minteer, Sarah A. , Griffin, Joan M. , Pachman, Deirdre R. , Ruddy, Kathryn J. , Cheville, Andrea , Fischer, Kristin , Ridgeway, Jennifer L , Redmond, Sarah , Griffin, Joan M , Ruddy, Kathryn J , Cheville, Andrea L , Austin, Jessica D , Rutten, Lila J. Finney

Mayo Clinic

JCO Oncology Practice | August 6, 2024 | Volume: 21 | Issue: 2 | Pages: 209-217

10.1200/op.24.00280 | PMID 39106420 Get It

PURPOSE The enhanced, electronic health record (EHR)–facilitated cancer symptom control (E2C2) trial is a cohort cluster-randomized, stepped-wedge, hybrid type II trial that leverages EHR systems to facilitate a collaborative care model (CCM) approach with the goal of improving cancer symptom management. Understanding factors that influence care team adoption of EHR systems remains a critical understudied area of research. This study examines how oncology care teams' perceptions regarding the feasibility, acceptability, and appropriateness of E2C2 EHR systems preimplementation were associated with adoption 3 months after implementation and characterizes differences in adoption by individual- and system-level factors. METHODS Care team members completed an electronic survey before and 3 months after implementation of E2C2 for their respective sequence. Adoption was defined as frequency of use to statements aligned with care team–directed EHR systems designed to facilitate CCM approaches. Chi-square tests assessed differences in adoption while logistic regression models estimated associations between baseline mean scores of acceptability, feasibility, and appropriateness on care team adoption at 3 months. RESULTS Results from 94 care team members (37.2% oncologists, 72.6% female, 55.3% in their role for 6+ years) found that adoption rates ranged from 48.9% to 71.7%, with significant differences observed by location (community-based health care systems v tertiary medical center) and professional role. Adjusting for professional role, care team members reporting higher levels of perceived acceptability and appropriateness at baseline had greater odds of adopting EHR systems at 3 months. CONCLUSION EHR systems perceived as acceptable and appropriate are more likely to be adopted by oncology care teams in our sample. Future implementation efforts should consider tailored strategies to facilitate adoption of EHR systems designed to promote CCM-based approaches to improve cancer symptom management.
Accurate and Automated Genotyping of the CFTR Poly-T/TG Tract with CFTR-TIPS
Ding, Qiliang , Hofich, Christopher D , Kellogg, Tifani B., Kuennen, Rhonda K., Paxton, Kaitlin N., Thieke, Sarah, Rumilla, Kandelaria M., Hasadsri, Linda , Thieke, Sarah M, Hasadsri, Linda

Mayo Clinic

International Journal of Molecular Sciences | August 5, 2024 | Volume: 25 | Issue: 15 | Pages: 8533

10.3390/ijms25158533 | PMID 39126101 Get It

Cystic fibrosis is caused by biallelic pathogenic variants in the CFTR gene, which contains a polymorphic (TG)mTn sequence (the “poly-T/TG tract”) in intron 9. While T9 and T7 alleles are benign, T5 alleles with longer TG repeats, e.g., (TG)12T5 and (TG)13T5, are clinically significant. Thus, professional medical societies currently recommend reporting the TG repeat size when T5 is detected. Sanger sequencing is a cost-effective method of genotyping the (TG)mTn tract; however, its polymorphic length substantially complicates data analysis. We developed CFTR-TIPS, a freely available web-based software tool that infers the (TG)mTn genotype from Sanger sequencing data. This tool detects the (TG)mTn tract in the chromatograms, quantifies goodness of fit with expected patterns, and visualizes the results in a graphical user interface. It is broadly compatible with any Sanger chromatogram that contains the (TG)mTn tract ± 15 bp. We evaluated CFTR-TIPS using 835 clinical samples previously analyzed in a CLIA-certified, CAP-accredited laboratory. When operated fully automatically, CFTR-TIPS achieved 99.8% concordance with our clinically validated manual workflow, while generally taking less than 10 s per sample. There were two discordant samples: one due to a co-occurring heterozygous duplication that confounded the tool and the other due to incomplete (TG)mTn tract detection in the reverse chromatogram. No clinically significant misclassifications were observed. CFTR-TIPS is a free, accurate, and rapid tool for CFTR (TG)mTn tract genotyping using cost-effective Sanger sequencing. This tool is suitable both for automated use and as an aid to manual review to enhance accuracy and reduce analysis time.